 Arrowheads stock dropped 25 on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, theres another clinical candidate targeting a large multi-billion dollar market like JNJ-3989 for the treatment of patients with Hepatitis B. 